Form 4: Amgen Executive Equity Grant Disclosure
Statement of Changes in Beneficial Ownership
Amgen EVP and General Counsel Jonathan P. Graham received equity grants including 2,609 RSUs and 17,022 stock options.
Summary
- Jonathan P. Graham, EVP & General Counsel, was granted 2,609 Restricted Stock Units (RSUs) on May 5, 2026.
- The reporting person was also granted 17,022 non-qualified stock options with an exercise price of $329.59.
- A total of 408 shares were withheld by the company to satisfy tax obligations related to the transaction.
- Following these transactions, the reporting person holds 40,211 shares of Amgen common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding executive compensation with no immediate impact on company operations.
Positives
- Equity grants align executive interests with long-term shareholder value creation.
- The reporting person maintains a significant direct ownership stake of 40,211 shares.
Negatives
- The transaction involved the withholding of 408 shares for tax purposes, which is a standard but dilutive event.
Risks
- Future value of the granted options is dependent on the company's stock price exceeding the $329.59 exercise price.
- Vesting schedules create long-term retention requirements for the executive.
Future Outlook
The grants vest in four equal annual installments of 25% each, beginning May 5, 2027, indicating a multi-year retention strategy.
Industry Context
StockSavvy.ai notes that standard executive equity compensation filings like this are routine in the biopharmaceutical sector, reflecting typical corporate governance practices for retaining senior leadership.
Comparison to Industry Standards
- The use of four-year vesting schedules is consistent with standard executive compensation practices among large-cap pharmaceutical companies like Pfizer, Merck, and Bristol Myers Squibb.
Stakeholder Impact
- Minimal impact on shareholders as these are standard compensatory grants.
Next Steps
- Vesting of the first 25% of RSUs and options on May 5, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/05/2026 | Date of RSU and stock option grants. |
| 05/06/2026 | Date of tax-related share withholding and filing date. |
| 05/05/2027 | Commencement of vesting for RSUs and stock options. |
| 05/05/2036 | Expiration date for the granted stock options. |
Keywords
Amgen, AMGN, Form 4, Insider Trading, Equity Incentive Plan, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.